<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963976</url>
  </required_header>
  <id_info>
    <org_study_id>ICHADAPT513000128</org_study_id>
    <nct_id>NCT00963976</nct_id>
  </id_info>
  <brief_title>Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial</brief_title>
  <acronym>ICH ADAPT</acronym>
  <official_title>Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Heritage Foundation for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Management of blood pressure (BP) in the acute phase of intracerebral hemorrhage
      (ICH) remains controversial. Although it has been established that there is a transient
      moderate reduction of perihematoma cerebral blood flow (CBF) in acute ICH, the effect of BP
      treatment is unknown. The potential for exacerbation of CBF has precluded routine aggressive
      BP reduction.

      Aim and Hypothesis: The primary study aim is to demonstrate the feasibility and safety of
      acute BP reduction to &lt; 150 mmHg systolic using a standardized protocol in ICH patients. It
      is hypothesized that CTP will not demonstrate evidence of perihematoma ischemia following
      acute BP reduction.

      Design: ICH ADAPT is a randomized blinded endpoint trial. Acutely hypertensive ICH patients
      are randomized to a target systolic BP of &lt; 150 mmHg or &lt; 180 mmHg. Patients are treated with
      intravenous (IV) labetalol/hydralazine/enalapril.

      Study Outcomes: The primary outcome is cerebral blood flow in the perihematoma region,
      measured with CT perfusion, 2 hours after randomization. Secondary outcomes include the
      difference in BP at 1 and 2 hours post-randomization in the two treatment groups and hematoma
      expansion rates at 24 hours.

      Discussion: ICH ADAPT is the only randomized trial designed specifically to identify any
      hemodynamic changes in the perihematoma region secondary to aggressive BP management. The
      results of this trial will facilitate ongoing and future studies aimed at determining the
      efficacy of rapid BP reduction in acute ICH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is cerebral blood flow in the perihematoma region, measured with CT perfusion, 2 hours after randomization.</measure>
    <time_frame>2 hours post randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematoma expansion rates at 24 hours.</measure>
    <time_frame>24 hours post randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Target systolic BP &lt; 150 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systolic blood pressure will be reduced to &lt;150 mmHg within 1 hour of randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Target systolic BP &lt; 180 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systolic blood pressure will be reduced, to &lt;180 mmHg within 1 hour of randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>labetalol/hydralazine/enalapril</intervention_name>
    <description>Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).</description>
    <arm_group_label>Target systolic BP &lt; 150 mmHg</arm_group_label>
    <arm_group_label>Target systolic BP &lt; 180 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Acute primary ICH demonstrated with CT scan

          -  Onset ≤ 24 h prior to randomization

        Exclusion Criteria:

          -  Contraindication to BP reduction i.e., severe arterial stenosis or high-grade stenotic
             valvular heart disease

          -  Indication for urgent BP reduction i.e., hypertensive encephalopathy, or aortic
             dissection

          -  Definite evidence that the ICH is secondary to underlying cerebral or vascular
             pathology, i.e., AVM, aneurysm, tumour, trauma, vasculitis, or hemorrhagic
             transformation of an ischemic infarct

          -  Previous ischemic stroke within 30 days of current event NB: Prior ICH is not an
             exclusion criterion

          -  Planned surgical resection of hematoma NB: Extraventricular Drain placement is not an
             exclusion criterion

          -  Contraindication to CT perfusion imaging (i.e. contrast allergy, metformin use or
             Creatinine &gt;160 μmol/l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>February 24, 2012</last_update_submitted>
  <last_update_submitted_qc>February 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Ken Butcher</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cerebral Blood Flow</keyword>
  <keyword>CT Perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Hydralazine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

